<DOC>
	<DOC>NCT00757731</DOC>
	<brief_summary>Investigation of the long-term (12 months) efficacy and safety of milnacipran used in the treatment of fibromyalgia syndrome.</brief_summary>
	<brief_title>FMS European Long-Term Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>patient who completed the 3month F02207 GE 302 study patient with a diagnosis of fibromyalgia according to the 1990 ACR criteria at entry of F02207 GE 302 study known hypersensitivity to milnacipran major depressive episode significant risk of suicide generalised anxiety disorder substance abuse clinically significant cardiac disease pulmonary dysfunction active liver disease renal impairment autoimmune disease current systemic infection epileptic active cancer severe sleep apnoea active peptic ulcer inflammatory bowel disease unstable endocrine disease (for men) prostatic enlargement or other genitourinary disorders (for women) pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>